Literature DB >> 6630057

Immunoactive peptides, FK-156 and FK-565. III. Enhancement of host defense mechanisms against infection.

Y Mine, Y Watanabe, S Tawara, Y Yokota, M Nishida, S Goto, S Kuwahara.   

Abstract

We investigated the effect of immunoactive peptides, FK-156 and FK-565 on host defense mechanisms against microbial invasion. It was shown that these drugs given to normal mice increased the counts of phagocytes in both peripheral blood and peritoneal cavity, and enhanced the chemotactic, phagocytic and killing activities of peritoneal macrophages and polymorphonuclear leukocytes, and stimulated the phagocytic function of the reticuloendothelial system. Enhanced host resistance to microbial infection by these immunoactive peptides might be induced by both increase in counts and enhancement of functions of phagocytes. FK-156 restored decreased counts and functions of phagocytes in mice immunosuppressed by cyclophosphamide, hydrocortisone or tumor. These findings suggest that these immunoactive peptides could be applied to prevent intractable infection in immunocompromised hosts.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6630057     DOI: 10.7164/antibiotics.36.1059

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  13 in total

1.  Immunomodulatory and therapeutic properties of FK-565 in mice.

Authors:  J E Talmadge; B Lenz; M Schneider; H Phillips; C Long
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 2.  Unleashing the therapeutic potential of NOD-like receptors.

Authors:  Kaoru Geddes; João G Magalhães; Stephen E Girardin
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

3.  Gut microbes extend reach to systemic innate immunity.

Authors:  Dana J Philpott; Stephen E Girardin
Journal:  Nat Med       Date:  2010-02       Impact factor: 53.440

4.  Effect of anticancer drugs on the release of interferon gamma in vitro.

Authors:  K Ahmed; P H van der Meide; J L Turk
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Effect of anticancer agents neothramycin, aclacinomycin, FK-565 and FK-156 on the release of interleukin-2 and interleukin-1 in vitro.

Authors:  K Ahmed; J L Turk
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Structure-activity relationships in nucleotide oligomerization domain 1 (Nod1) agonistic γ-glutamyldiaminopimelic acid derivatives.

Authors:  Geetanjali Agnihotri; Rehman Ukani; Subbalakshmi S Malladi; Hemamali J Warshakoon; Rajalakshmi Balakrishna; Xinkun Wang; Sunil A David
Journal:  J Med Chem       Date:  2011-02-07       Impact factor: 7.446

7.  Bordetella pertussis tracheal cytotoxin and other muramyl peptides: distinct structure-activity relationships for respiratory epithelial cytopathology.

Authors:  K E Luker; J L Collier; E W Kolodziej; G R Marshall; W E Goldman
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

8.  Effect of anticancer drugs on the release of interleukin-6 in vitro.

Authors:  S I Hasan; B A Blaney; J L Turk
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

9.  Nod1 signaling overcomes resistance of S. pneumoniae to opsonophagocytic killing.

Authors:  Elena S Lysenko; Thomas B Clarke; Mikhail Shchepetov; Adam J Ratner; David I Roper; Christopher G Dowson; Jeffrey N Weiser
Journal:  PLoS Pathog       Date:  2007-08-24       Impact factor: 6.823

10.  Cyclosporine A impairs nucleotide binding oligomerization domain (Nod1)-mediated innate antibacterial renal defenses in mice and human transplant recipients.

Authors:  Emilie Tourneur; Sanae Ben Mkaddem; Cécilia Chassin; Marcelle Bens; Jean-Michel Goujon; Nicolas Charles; Christophe Pellefigues; Meryem Aloulou; Alexandre Hertig; Renato C Monteiro; Stephen E Girardin; Dana J Philpott; Eric Rondeau; Carole Elbim; Catherine Werts; Alain Vandewalle
Journal:  PLoS Pathog       Date:  2013-01-31       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.